Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,216 across all filing types
Latest filing 2025-08-05 Earnings Release
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 5, 2025, by Pacira BioSciences, Inc. It announces the issuance of a press release containing financial results for the second quarter ended June 30, 2025. The document itself does not contain the financial results but references an attached earnings press release (Exhibit 99.1). The length of the document is 3392 characters, which is relatively short and primarily serves as an announcement of the earnings release rather than the release itself. According to the rules, such a document is best classified as an Earnings Release (ER) since it announces quarterly financial results and includes the press release text as an exhibit. The Form 8-K is a common vehicle for earnings releases. Therefore, the classification is ER with high confidence.
2025-08-05 English
FORM 4
Director's Dealing
2025-08-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to report unscheduled material events or corporate changes of importance to shareholders. The content describes a workforce reduction due to manufacturing efficiencies, including estimated charges and operational impacts. It also includes a communication to employees and forward-looking statements. There are no comprehensive financial statements or detailed financial analysis typical of Annual Reports (10-K) or Interim Reports (IR). The document is not an earnings release, proxy statement, or management discussion. It is a regulatory filing reporting a significant corporate event. Therefore, it fits best under Regulatory Filings (RNS). The document length and detail confirm it is not a brief announcement or certification but a substantive report of a corporate event.
2025-07-10 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC by Pacira BioSciences, Inc. dated July 3, 2025. It reports the entry into a material definitive agreement, specifically a new credit agreement with Wells Fargo Bank, and the termination of a previous credit agreement. The content focuses on financing activities, including details of the credit facility, interest rates, covenants, and repayment of prior indebtedness. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The primary subject is an update on the company's capital structure and financing arrangements. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement or certification. Confidence is high due to clear identification of the credit agreement and financing details.
2025-07-07 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 10, 2025. It reports on the Annual Meeting of Stockholders, including voting results on various proposals such as election of directors, ratification of auditors, advisory votes on executive compensation, and approval of an amended stock incentive plan. The document primarily provides official results from shareholder votes at the Annual Meeting. It is not a full annual report, earnings release, or management discussion, but rather a formal announcement of voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (6304 characters) and content confirm it is not merely a brief announcement or proxy solicitation but a detailed voting results report.
2025-06-13 English
FORM 4
Director's Dealing
2025-06-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.